Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.

Adjuvants, Immunologic / administration & dosage Animals Antibodies, Neutralizing / blood Antibodies, Viral / blood COVID-19 / epidemiology COVID-19 Vaccines / administration & dosage Disease Models, Animal Drug Combinations Drug Compounding / methods Immunity, Humoral Immunogenicity, Vaccine / immunology Macaca mulatta Male Pandemics / prevention & control Polysorbates / administration & dosage Recombinant Proteins / immunology SARS-CoV-2 / immunology Spike Glycoprotein, Coronavirus / immunology Squalene / administration & dosage Nicotiana / metabolism Treatment Outcome Vaccination / methods Vaccines, Virus-Like Particle / administration & dosage alpha-Tocopherol / administration & dosage

AS03 CpG1018 Non-humane primates SARS-CoV-2 Virus-like particles

Journal

Cellular & molecular immunology

ISSN: 2042-0226

Titre abrégé: Cell Mol Immunol

Pays: China

ID NLM: 101242872

Informations de publication

Date de publication:
02 2022

Historique:

received: 30 08 2021

accepted: 15 11 2021

pubmed: 6 1 2022

medline: 11 2 2022

entrez: 5 1 2022

Statut: ppublish

Résumé

Although antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or cytidine-phospho-guanosine (CpG) 1018. Although a single dose of the unadjuvanted CoVLP vaccine candidate stimulated humoral and cell-mediated immune responses, booster immunization (at 28 days after priming) and adjuvant administration significantly improved both responses, with higher immunogenicity and protection provided by the AS03-adjuvanted CoVLP. Fifteen micrograms of CoVLP adjuvanted with AS03 induced a polyfunctional interleukin-2 (IL-2)-driven response and IL-4 expression in CD4 T cells. Animals were challenged by multiple routes (i.e., intratracheal, intranasal, and ocular) with a total viral dose of 10

Identifiants

DOI: 10.1038/s41423-021-00809-2 PMID: 34983950 PMC: PMC8727235

pubmed: 34983950

doi: 10.1038/s41423-021-00809-2

pii: 10.1038/s41423-021-00809-2

pmc: PMC8727235

doi:

Substances chimiques

Adjuvants, Immunologic 0

Antibodies, Neutralizing 0

Antibodies, Viral 0

COVID-19 Vaccines 0

Drug Combinations 0

Polysorbates 0

Recombinant Proteins 0

Spike Glycoprotein, Coronavirus 0

Vaccines, Virus-Like Particle 0

spike protein, SARS-CoV-2 0

Squalene 7QWM220FJH

AS03 adjuvant A7YT618XBV

alpha-Tocopherol H4N855PNZ1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

222-233

Subventions

Organisme : NIH HHS

ID : P51 OD011104

Pays : United States

Informations de copyright

Références

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.

pubmed: 32221306 pmcid: 7100515 doi: 10.1038/s41467-020-15562-9

Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–61.

pubmed: 27578435 pmcid: 5457962 doi: 10.1146/annurev-virology-110615-042301

Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020;10:14991.

pubmed: 32929138 pmcid: 7490396 doi: 10.1038/s41598-020-71748-7

Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779–84.e775.

pubmed: 32362314 pmcid: 7194065 doi: 10.1016/j.molcel.2020.04.022

D'aoust MA, Couture MM, Charland N, Trépanier S, Landry N, Ors F, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8:607–19.

pubmed: 20199612 doi: 10.1111/j.1467-7652.2009.00496.x

Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–36.

pubmed: 19198616 pmcid: 2750777 doi: 10.1038/nrmicro2090

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA. 2017;114:E7348–57.

pubmed: 28807998 pmcid: 5584442 doi: 10.1073/pnas.1707304114

Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21.

pubmed: 29801750 doi: 10.1016/j.smim.2018.05.001

Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 2014;13:299–312.

pubmed: 24308579 doi: 10.1586/14760584.2014.863715

Campbell JD. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 2017;1494:15–27.

pubmed: 27718183 doi: 10.1007/978-1-4939-6445-1_2

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461–73.

pubmed: 21256188 doi: 10.1016/j.vaccine.2011.01.011

Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, et al. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol. 2017;8:943.

pubmed: 28855902 pmcid: 5557780 doi: 10.3389/fimmu.2017.00943

De Mot L, Bechtold V, Bol V, Callegaro A, Coccia M, Essaghir A, et al. Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. Sci Transl Med. 2020;12:eaay8618.

pubmed: 33177181 doi: 10.1126/scitranslmed.aay8618

Howard LM, Goll JB, Jensen TL, Hoek KL, Prasad N, Gelber CE, et al. AS03-adjuvanted H5N1 avian influenza vaccine modulates early innate immune signatures in human peripheral blood mononuclear cells. J Infect Dis. 2019;219:1786–98.

pubmed: 30566602 doi: 10.1093/infdis/jiy721

Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines. 2018;3:40.

pubmed: 30302282 pmcid: 6167326 doi: 10.1038/s41541-018-0076-2

Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580–9.

pubmed: 17707753 doi: 10.1016/S0140-6736(07)61297-5

Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31:443–54.

pubmed: 21174144 doi: 10.1007/s10875-010-9490-6

Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, et al. Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine. 2019;37:3006–21.

pubmed: 31031030 doi: 10.1016/j.vaccine.2019.04.048

Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27:1071–8.

pubmed: 34007070 pmcid: 8205852 doi: 10.1038/s41591-021-01370-1

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.

pubmed: 32075877 pmcid: 7164637 doi: 10.1126/science.abb2507

Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5:eabe0240.

pubmed: 33288645 pmcid: 7857392 doi: 10.1126/sciimmunol.abe0240

Fahlberg MD, Blair RV, Doyle-Meyers LA, Midkiff CC, Zenere G, Russell-Lodrigue KE, et al. Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nat Commun. 2020;11:6078.

pubmed: 33247138 pmcid: 7695721 doi: 10.1038/s41467-020-19967-4

Blair RV, Vaccari M, Doyle-Meyers LA, Roy CJ, Russell-Lodrigue K, Fahlberg M, et al. Acute respiratory distress in aged, SARS-CoV-2-infected African Green monkeys but not Rhesus macaques. Am J Pathol. 2021;191:274–82.

pubmed: 33171111 pmcid: 7648506 doi: 10.1016/j.ajpath.2020.10.016

Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L, Schulz J, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020;585:268–72.

pubmed: 32396922 pmcid: 7486227 doi: 10.1038/s41586-020-2324-7

Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181:914–21.e910.

pubmed: 32330414 pmcid: 7179501 doi: 10.1016/j.cell.2020.04.011

Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine. 2012;30:5445–8.

pubmed: 22704926 doi: 10.1016/j.vaccine.2012.05.074

Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31:5300–5.

pubmed: 23727002 doi: 10.1016/j.vaccine.2013.05.068

Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clin Immunol. 2016;169:16–27.

pubmed: 27236001 doi: 10.1016/j.clim.2016.05.007

Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12:1346.

pubmed: 33649323 pmcid: 7921634 doi: 10.1038/s41467-021-21634-1

Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594:253–8.

pubmed: 33873199 doi: 10.1038/s41586-021-03530-2

Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29:1137–150.e6.

pubmed: 34133950 pmcid: 8175625 doi: 10.1016/j.chom.2021.06.001

Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–11.

pubmed: 32434945 pmcid: 7243363 doi: 10.1126/science.abc6284

Bartsch YC, Fischinger S, Siddiqui SM, Chen Z, Yu J, Gebre M, et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat Commun. 2021;12:1018.

pubmed: 33589636 pmcid: 7884400 doi: 10.1038/s41467-021-21336-8

McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630–4.

pubmed: 33276369 doi: 10.1038/s41586-020-03041-6

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.

pubmed: 33408181 doi: 10.1126/science.abf4063

Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22:74–85.

pubmed: 32999467 doi: 10.1038/s41590-020-00808-x

Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e1019.

pubmed: 33010815 pmcid: 7494270 doi: 10.1016/j.cell.2020.09.038

Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–80.

pubmed: 33497610 pmcid: 7803150 doi: 10.1016/j.cell.2021.01.007

Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84:1289–301.

pubmed: 19906920 doi: 10.1128/JVI.01281-09

Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84:9318–25.

pubmed: 20610717 pmcid: 2937604 doi: 10.1128/JVI.01049-10

Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44:1379–91.

pubmed: 27287409 pmcid: 4917442 doi: 10.1016/j.immuni.2016.05.006

Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytom Part A. 2008;73:975–83.

doi: 10.1002/cyto.a.20643

Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med. 2012;209:1391–5.

pubmed: 22851641 pmcid: 3420330 doi: 10.1084/jem.20121517

Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8:247–58.

pubmed: 18323851 doi: 10.1038/nri2274

Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, Goodwin B, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021;20:e100355.

Deng N, Weaver JM, Mosmann TR. Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2+IFNgamma- Thpp cells. PLoS ONE. 2014;9:e95986.

pubmed: 24788814 pmcid: 4006810 doi: 10.1371/journal.pone.0095986

Weaver JM, Yang H, Roumanes D, Lee FE, Wu H, Treanor JJ, et al. Increase in IFNgamma(-)IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza. PLoS ONE. 2013;8:e57275.

pubmed: 23526940 pmcid: 3603952 doi: 10.1371/journal.pone.0057275

Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–63.

pubmed: 21314428 doi: 10.1146/annurev-immunol-031210-101400

Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75:14–24.

pubmed: 26044597 pmcid: 4532589 doi: 10.1016/j.cyto.2015.05.010

Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586:583–8.

pubmed: 32731257 pmcid: 7581548 doi: 10.1038/s41586-020-2607-z

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537.

pubmed: 32251717 pmcid: 7195002 doi: 10.1016/j.autrev.2020.102537

Pandolfi L, Fossali T, Frangipane V, Bozzini S, Morosini M, D'Amato M, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. BMC Pulm Med. 2020;20:301.

pubmed: 33198751 pmcid: 7668012 doi: 10.1186/s12890-020-01343-z

Ye J, Zhang B, Xu J, Chang Q, McNutt MA, Korteweg C, et al. Molecular pathology in the lungs of severe acute respiratory syndrome patients. Am J Pathol. 2007;170:538–45.

pubmed: 17255322 pmcid: 1851867 doi: 10.2353/ajpath.2007.060469

Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–40.

pubmed: 32526193 pmcid: 7279758 doi: 10.1016/S1473-3099(20)30434-5

Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681–6.

pubmed: 32473124 pmcid: 7255143 doi: 10.1016/S2213-2600(20)30243-5

Schurink B, Roos E, Radonic T, Barbe E, Bouman C, de Boer HH, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290–99.

pubmed: 33015653 pmcid: 7518879 doi: 10.1016/S2666-5247(20)30144-0

Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–94.

pubmed: 33524311 pmcid: 7906655 doi: 10.1016/S0140-6736(21)00241-5